Skip to content

Effect of 10Hz rTMS as an adjunctive to pregabalin in addition to Pregabalin in Central Post Stroke Pain : A randomised double blind placebo controlled trial

To compare the efficacy and tolerability of adjunctive high frequency rTMS plus pregabalin over pregabalin alone in patients with CPSP: A randomized double- blind cross over trial in single-center tertiary care referral teaching hospital. - RTMS-CPSP

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/07/071057
Enrollment
90
Registered
2024-07-23
Start date
Unknown
Completion date
Unknown
Last updated
2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G998- Other specified disorders of nervous system in diseases classified elsewhere

Interventions

Intervention1: High frequency repetitive transmagnetic stimulation(rTMS): 3 sessions of monthly HF rTMS for 3 consecutive days in each session followed by cross over to another group. Total duration o

Sponsors

Professor Jayantee Kalita
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Age more than 18 years, those fulfilling the diagnostic criteria of CPSP, pain intensity more than equal to 4 on a Visual analog scale (VAS, 0 to 10 with 0 indicating no pain and 10 the worst pain imaginable), those who will give the consent to participate in the study

Exclusion criteria

Exclusion criteria: Age more than 70 years and less than 18 years, patients with less than 4 pain on VAS, epilepsy, pregnancy, metallic implant, pacemaker, painful peripheral neuropathy, complex regional pain syndrome, psychiatric and post-head injury pain disorders, bony defect of scalp, chronic renal or liver failure, heart failure, cancer, and those with a history of drug allergy will be excluded. The patients with dementia and aphasia, and those who are not willing to give consent will also be excluded.

Design outcomes

Primary

MeasureTime frame
Greater than 50% reduction in pain on visual analog scale.Timepoint: Baseline, 1 month and at 3 months

Secondary

MeasureTime frame
1. Reduction in pain from baseline on visual analog scale (VAS) 2. Improvement in scores of Neuropsychiatric Inventory (NPI), Hospital anxiety depression scale (HADS) score, Pittsburgh sleep quality index (PSQI), Quality of life index (QOL), Median Somatosensory evoked potentials, Mechanical static, Mechanical dynamic allodynia and Cold allodynia.Timepoint: baseline, 1 month and at 3 months

Countries

India

Contacts

Public ContactJayantee Kalita

Sanjay Gandhi Post Graduate Institute of Medical Sciences

jayanteek@yahoo.com05222494177

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026